Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biodesix (BDSX) Share-based Compensation (2019 - 2025)

Historic Share-based Compensation for Biodesix (BDSX) over the last 7 years, with Q3 2025 value amounting to $1.1 million.

  • Biodesix's Share-based Compensation fell 3049.5% to $1.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.3 million, marking a year-over-year decrease of 3292.53%. This contributed to the annual value of $6.6 million for FY2024, which is 2354.36% up from last year.
  • As of Q3 2025, Biodesix's Share-based Compensation stood at $1.1 million, which was down 3049.5% from $1.0 million recorded in Q2 2025.
  • Biodesix's Share-based Compensation's 5-year high stood at $2.6 million during Q1 2024, with a 5-year trough of $539000.0 in Q2 2021.
  • Over the past 5 years, Biodesix's median Share-based Compensation value was $1.3 million (recorded in 2024), while the average stood at $1.4 million.
  • Within the past 5 years, the most significant YoY rise in Biodesix's Share-based Compensation was 128600.0% (2021), while the steepest drop was 6435.0% (2021).
  • Biodesix's Share-based Compensation (Quarter) stood at $1.3 million in 2021, then soared by 63.93% to $2.1 million in 2022, then crashed by 47.95% to $1.1 million in 2023, then increased by 17.02% to $1.3 million in 2024, then decreased by 16.76% to $1.1 million in 2025.
  • Its Share-based Compensation stands at $1.1 million for Q3 2025, versus $1.0 million for Q2 2025 and $972000.0 for Q1 2025.